抗精神病药物市场规模、份额和成长分析（按治疗层级、疾病、药物、分销管道和地区）- 2025-2032 年产业预测

2023 年抗精神病药物市场规模价值 172.7 亿美元，预计将从 2024 年的 182.7 亿美元增长到 2032 年的 286.9 亿美元，预测期内（2025-2032 年）的复合年增长率为 5.8%。

全球抗精神病药物市场正在经历强劲增长，这得益于人们对精神健康问题的认识不断提高，以及政府和医疗机构为促进早期诊断和治疗而做出的共同努力。思觉失调症和躁郁症等精神疾病的增加推动了对第一代和第二代抗精神病药物的需求。长效注射剂（LAI）和基于药物基因组学的个人化治疗等创新正在提高患者的依从性和治疗效果。随着提供即时洞察的数位疗法的兴起，市场也正在经历向非典型抗精神病药物的转变。最近的收购和 FDA核准，例如强生公司以 150 亿美元收购 Intra-Cellular Therapies，凸显了旨在推进精神病护理和满足对更安全、更有效治疗的日益增长的需求的战略投资。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 监管格局
• 专利分析

抗精神病药物市场规模（依治疗层级和复合年增长率） (2025-2032)

• 市场概况
• 第一代
• 第二代
• 第三代

抗精神病药物市场规模（按疾病和复合年增长率） (2025-2032)

• 市场概况
• 思觉失调症
• 躁郁症
• 单相忧郁症
• 失智
• 其他疾病

抗精神病药物市场规模（按药物类型和复合年增长率） (2025-2032)

• 市场概况
• Risperidone
• Quetiapine
• Olanzapine
• Aripiprazole
• Brexpiprazole
• 帕利哌酮棕榈酸酯
• 其他的

抗精神病药物市场规模（按分销管道和复合年增长率） (2025-2032)

• 市场概况
• 医院药房
• 药局和药房
• 网路药局

抗精神病药物市场规模（按地区划分）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Johnson & Johnson（USA）
• Otsuka Pharmaceutical Co., Ltd.（Japan）
• Pfizer Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Eli Lilly and Company（USA）
• AstraZeneca plc（UK）
• GlaxoSmithKline plc（UK）
• AbbVie Inc.（USA）
• Bristol-Myers Squibb（USA）
• H. Lundbeck A/S（Denmark）
• Sumitomo Pharma Co., Ltd.（Japan）
• Alkermes plc（Ireland）
• Dr. Reddy's Laboratories（India）
• Amgen Inc.（USA）
• Sanofi SA（France）
• Merck & Co., Inc.（USA）
• Novartis International AG（Switzerland）
• Roche Holding AG（Switzerland）
• Takeda Pharmaceutical Company Limited（Japan）
• Sun Pharmaceutical Industries Ltd.（India）

结论和建议

Antipsychotic Drugs Market size was valued at USD 17.27 billion in 2023 and is poised to grow from USD 18.27 billion in 2024 to USD 28.69 billion by 2032, growing at a CAGR of 5.8% during the forecast period (2025-2032).

The global antipsychotic drugs market is witnessing robust growth, fueled by increased awareness of mental health issues and concerted efforts from governments and health organizations to promote early diagnosis and treatment. The rise in mental health disorders, such as schizophrenia and bipolar disorder, is driving demand for both first- and second-generation antipsychotic medications. Innovations in long-acting injectables (LAIs) and tailored therapies through pharmacogenomics are enhancing patient adherence and treatment outcomes. The market is also experiencing a shift towards atypical antipsychotics, coupled with the rise of digital therapeutics that provide real-time insights. Recent acquisitions and FDA approvals, such as Johnson & Johnson's $15 billion acquisition of Intra-Cellular Therapies, highlight strategic investments aimed at advancing psychiatric care and accommodating the growing demand for safer, effective treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Antipsychotic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Antipsychotic Drugs Market Segments Analysis

Global Antipsychotic Drugs Market is segmented by Therapeutic Class, Disease, Drug, Distribution Channel and region. Based on Therapeutic Class, the market is segmented into First Generation, Second Generation and Third Generation. Based on Disease, the market is segmented into Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia and Other Diseases. Based on Drug, the market is segmented into Risperidone, Quetiapine, Olanzapine, Aripiprazole, Brexpiprazole, Paliperidone Palmitate and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Antipsychotic Drugs Market

A significant factor fueling the growth of the global antipsychotic drugs market is the escalating incidence of mental health disorders, such as schizophrenia and bipolar disorder. As awareness of these conditions rises, there is a growing demand for innovative treatment options as well as improved access to psychiatric care across the globe. This heightened understanding of mental health issues not only drives the development of new therapies but also emphasizes the necessity for comprehensive support systems for individuals affected by these disorders. Consequently, this trend is propelling the expansion of the antipsychotic drug market worldwide.

Restraints in the Antipsychotic Drugs Market

The global antipsychotic drugs market faces notable restraints, primarily due to regulatory challenges and protracted approval processes. These stringent regulations and extended clinical trial requirements hinder the timely introduction of new therapies, thereby impeding the speed at which groundbreaking medications can become available to patients. Such obstacles particularly affect market expansion in regions with rigid regulatory environments, further constraining the overall growth potential of the antipsychotic drug sector. Consequently, manufacturers and stakeholders must navigate these regulatory complexities, which can significantly delay the development and commercialization of innovative treatment options for mental health disorders.

Market Trends of the Antipsychotic Drugs Market

The antipsychotic drugs market is experiencing a notable trend towards the increasing demand for long-acting injectable antipsychotics, driven by the need for improved management of chronic psychiatric disorders such as schizophrenia. These innovative formulations allow for reduced dosing frequency, enhancing patient adherence and overall treatment effectiveness. Notably, pharmaceutical companies are investing in the development of new long-acting injectables that not only ensure sustained therapeutic efficacy but also prioritize patient convenience. This shift reflects a broader understanding of the complexities of mental health treatment, emphasizing the need for solutions that are both effective and user-friendly, positioning long-acting injectables as key players in the market's growth.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Antipsychotic Drugs Market Size by Therapeutic Class & CAGR (2025-2032)

• Market Overview
• First Generation
• Second Generation
• Third Generation

Global Antipsychotic Drugs Market Size by Disease & CAGR (2025-2032)

• Market Overview
• Schizophrenia
• Bipolar Disorder
• Unipolar Depression
• Dementia
• Other Diseases

Global Antipsychotic Drugs Market Size by Drug & CAGR (2025-2032)

• Market Overview
• Risperidone
• Quetiapine
• Olanzapine
• Aripiprazole
• Brexpiprazole
• Paliperidone Palmitate
• Others

Global Antipsychotic Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

Global Antipsychotic Drugs Market Size & CAGR (2025-2032)

• North America (Therapeutic Class, Disease, Drug, Distribution Channel)
  • US
  • Canada
• Europe (Therapeutic Class, Disease, Drug, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapeutic Class, Disease, Drug, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapeutic Class, Disease, Drug, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapeutic Class, Disease, Drug, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Pharma Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkermes plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations